The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

As many as 17% of men and 34% of women in the United States suffer from sleep apnea, and the numbers are increasing. KYW ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Regular-moderate intensity exercise, while avoiding very intense exercise is probably best for people in their 70s.

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Novo Nordisk A/S, GE HealthCare Technologies Inc. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...

Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular semaglutide medicines as one of the 15 additional drugs covered under Medicare Part ...

Eli Lilly markets its tirzepatide medicines ... subcutaneous semaglutide 7.2 mg compared with Wegovy and placebo in adults with obesity.

Instead, it's called tirzepatide. That could be a distinction ... Specifically, the company said semaglutide 7.2 milligram (mg) injections over a 72-week period resulted in an average weight ...

Speaking to The Straits Times in an exclusive interview on Jan 9 at MG’s exhibition booth at Suntec Singapore Convention and Exhibition Centre, the 76-year-old motor tycoon is driven to take a ...